Evaluating the efficacy of PARP inhibitor in ARID1A-deficient colorectal cancer: A ex vivo study
{{output}}
ARID1A mutations are a common occurrence in colorectal cancer (CRC) cells, but clinical therapeutic options targeting this anomaly remain unavailable. The loss of ARID1A functionality compromises DNA damage repair processes, potentially causing cancer cells to... ...
